Anavex Expands Management Team

NEW YORK, NY – December 2, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Ulrich Elben, PhD as Vice President of Preclinical Operations.…